<DOC>
	<DOCNO>NCT02469090</DOCNO>
	<brief_summary>A 12-week , prospective , multi-center , randomize , double-blind , placebo control , Phase 3 study L-Dopa responsive PD patient motor fluctuation ( `` OFF '' episode ) , design determine efficacy , safety tolerability APL-130277 .</brief_summary>
	<brief_title>Efficacy , Safety Tolerability Study APL-130277 Acute Treatment OFF Episodes Patients With Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Apomorphine</mesh_term>
	<criteria>Male female ≥ 18 year age . Clinical diagnosis Idiopathic PD , consistent UK Brain Bank Criteria . Clinically meaningful response LDopa welldefined early morning `` OFF '' episode , determine Investigator . Receiving stable dos LDopa/carbidopa ( immediate CR ) administer least 4 time per day OR Rytary™ administer 3 time per day , least 4 week initial Screening Visit No planned medication change ( ) surgical intervention anticipate course study . Patients must experience least one well define `` OFF '' episode per day total daily `` OFF '' time duration ≥ 2 hour wake day , base patient selfassessment . Stage III less modified Hoehn Yahr scale `` ON '' state . MMSE score &gt; 25 . A patient eligible study entry follow exclusion criterion meet : Atypical secondary parkinsonism . Previous treatment follow : neurosurgical procedure PD ; continuous s.c. apomorphine infusion ; Duodopa/Duopa . Treatment form s.c. apomorphine within 7 day prior initial Screening Visit ( SV1 ) . Patients stop s.c. apomorphine reason systemic safety concern lack efficacy may consider . Contraindications APOKYN® , hypersensitivity apomorphine hydrochloride ingredient APOKYN® ( notably sodium metabisulfite ) ; Tigan® ( trimethobenzamide hydrochloride ; patient US site ) ; domperidone ( patient nonUS site ) . Participation clinical trial within 30 day prior initial Screening Visit ( SV1 ) . Currently take selective 5HT3 antagonist ( i.e. , ondansetron , granisetron , dolasetron , palonosetron , alosetron ) , dopamine antagonist ( exclude quetiapine clozapine ) dopamine deplete agent . Drug alcohol dependency past 12 month . History malignant melanoma . Clinically significant medical , surgical , laboratory abnormality opinion Investigator . Major psychiatric disorder include , limited , dementia , bipolar disorder , psychosis , disorder , opinion Investigator , require ongoing treatment would make study participation unsafe make treatment compliance difficult . History clinically significant hallucination past 6 month . History clinically significant impulse control disorder ( ) . Dementia preclude provide informed consent would interfere participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>